2 completed, 2 not yet recruiting, 1 recruiting, 1 terminated. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 2, Not yet recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease | Phase 4 | Not yet recruiting | Viridian Therapeutics, Inc. | 30 | 2026-09-01 | 2026-09-21 |
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Teprotumumab N01, Methylprednisolone - Thyroid Eye Disease | Phase 4 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 92 | 2026-07-30 | 2026-08-13 |
| Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease Teprotumumab Injection [Tepezza] - Thyroid Eye Disease, Thyroid Eye Disease, TED | Phase 4 | Not yet recruiting | Sheba Medical Center | 40 | 2026-01-01 | 2025-12-30 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Teprotumumab, Placebo - Thyroid Eye Disease | Phase 4 | Completed | Amgen | 313 | 2021-09-16 | 2026-08-21 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease TEPEZZA, Placebo - Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease | Phase 4 | Completed | Amgen | 62 | 2021-09-02 | 2024-07-01 |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Hyaluronic Acid Gel injection, Saline injection - Thyroid Eye Disease | Phase 4 | Terminated | University of California, Los Angeles | 2 | 2013-12-01 | 2021-10-04 |
Graves Ophthalmopathy (7) · Bronchiolitis Obliterans Syndrome (1) · Exophthalmos (1) · Glaucoma (1) · Graves Disease (1) · Ocular Hypertension (1) · Sedentary Behavior (1) · Thyroid Diseases (1)
Autoimmune Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Endocrine System Diseases (7) · Eye Diseases (7) · Eye Diseases, Hereditary (7) · Genetic Diseases, Inborn (7) · Goiter (7) · Hyperthyroidism (7) · Immune System Diseases (7) · Orbital Diseases (7) · Exophthalmos (6) · Graves Disease (6) · Thyroid Diseases (6) · Behavior (1) · Bronchial Diseases (1)
teprotumumab (3) · Saline Solution (2) · Sodium Chloride (2) · Bimatoprost (1) · Latanoprost (1) · Methylprednisolone (1) · Prostaglandins, Synthetic (1) · Restylane (1) · Timolol (1) · Travoprost (1) · belotero balance (1) · tafluprost (1)
Amgen (2) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Sheba Medical Center (1) · Stanford University (1) · University of California, Los Angeles (1) · Viridian Therapeutics, Inc. (1)
United States (5) · China (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1)
Andrea L. Kossler, M.D. (1) · Daniel Rootman (1)